TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10195532

Group type: EXPERIMENTAL
Intervention: 1.2 mg/kg meperidine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg meperidine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 1.8 mg/kg meperidine
Number of subjects: 45

Group type: COMPARATOR
Intervention: All doses
Number of subjects: 45
Study: 7539668

Group type: EXPERIMENTAL
Intervention: r‐metHuG‐CSF (filgrastim) 10 micrograms/kg/day
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: r‐metHuG‐CSF (filgrastim) 30 micrograms/kg/day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no growth factor)
Number of subjects: 54
Study: 2405108

Group type: EXPERIMENTAL
Intervention: rIL-2 via splenic artery infusion
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: rIL-2 via hepatic artery infusion
Number of subjects: 28
Study: 7288433

Group type: EXPERIMENTAL
Intervention: Melatonin infusion (2.1 mg/min for 4 hours)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 4
Study: 31776782

Group type: EXPERIMENTAL
Intervention: WLS Optimum (specialized multivitamin supplement)
Number of subjects: 139

Group type: COMPARATOR
Intervention: sMVS (standard multivitamin supplement)
Number of subjects: 139
Study: 31566579

Group type: EXPERIMENTAL
Intervention: T3 (DNA at M0, M1, M3, M6 with protein coadministered at M3 and M6)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: T4 (protein and DNA coadministered at each vaccination visit)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: T3
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: T4
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: T3 and T4
Number of subjects: 104
Study: 26597394

Group type: EXPERIMENTAL
Intervention: Active extremity mobilization and neuromuscular electrical stimulation (NMES)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Only NMES
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Active extremity exercise training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group-1 (Active extremity mobilization and NMES)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group-2 (Only NMES)
Number of subjects: 30
Study: 25301760

Group type: COMPARATOR
Intervention: Control arm (long-term androgen deprivation therapy - ADT)
Number of subjects: 917
Study: 23331559

Group type: EXPERIMENTAL
Intervention: GSK2190915 100 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 22353410

Group type: EXPERIMENTAL
Intervention: Adhesive cements (RMGIC+DBA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Adhesive cements (RMGIC)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Adhesive cements (GIC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nonadhesive cements (ZP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nonadhesive cements (PC)
Number of subjects: 100
Study: 19335674

Group type: EXPERIMENTAL
Intervention: Strength and weight training exercises for 24 months
Number of subjects: 110

Group type: COMPARATOR
Intervention: Comparison group (no exercise)
Number of subjects: 110
Study: 16400056

Group type: EXPERIMENTAL
Intervention: 500 mg alpha-tocopherol/d
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 500 mg mixed tocopherols/d
Number of subjects: 58

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 58
Study: 15380045

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT), calcium, and vitamin D3
Number of subjects: 88

Group type: COMPARATOR
Intervention: Calcium and vitamin D3 alone
Number of subjects: 88
Study: 11673017

Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vagal Nerve Stimulation (VNS)
Number of subjects: 0
Study: 9163286

Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: TIPS
Number of subjects: 49
Study: 8217756

Group type: EXPERIMENTAL
Intervention: 0.1% tretinoin applied once daily for 40 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Vehicle cream applied once daily for 40 weeks
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 0.1% tretinoin
Number of subjects: 38

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 38
Study: 3296861

Group type: EXPERIMENTAL
Intervention: Anticoagulants (phenprocoumon or acenocoumarol)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Anticoagulants (phenprocoumon or acenocoumarol) plus pentoxifylline (800-1200 mg/day)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Irregular treatment with various vasodilators (xanthinolnicotinate, naftidrofuryl, pyridylmethanol, etc.)
Number of subjects: 113
Study: 31982095

Group type: EXPERIMENTAL
Intervention: Rater Training (RT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: No Training (Control)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Standardized assessments (OSATS GRS)
Number of subjects: 47
Study: 28961366

Group type: EXPERIMENTAL
Intervention: Burst stimulation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tonic stimulation
Number of subjects: 100
Study: 26708108

Group type: COMPARATOR
Intervention: Placebo CBD (0 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: CBD (200 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: CBD (400 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: CBD (800 mg)
Number of subjects: 31
Study: 25688926

Group type: EXPERIMENTAL
Intervention: Fresh kimchi
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fermented kimchi
Number of subjects: 24
Study: 23523222

Group type: EXPERIMENTAL
Intervention: Amniotic membrane
Number of subjects: 54

Group type: COMPARATOR
Intervention: Skin staples (control group)
Number of subjects: 54
Study: 21640044

Group type: EXPERIMENTAL
Intervention: FIN-RACo combination therapy (methotrexate, sulfasalazine, hydroxychloroquine, and prednisolone), n=69
Number of subjects: 129

Group type: COMPARATOR
Intervention: Single DMARD therapy (initially sulfasalazine with or without prednisolone), n=60
Number of subjects: 129
Study: 19920426

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided interscalene brachial plexus block with 10 mL of ropivacaine 0.75%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nerve stimulation interscalene brachial plexus block with 10 mL of ropivacaine 0.75%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nerve stimulation interscalene brachial plexus block
Number of subjects: 30
Study: 16512478

Group type: EXPERIMENTAL
Intervention: EGF/PGF ratio
Number of subjects: 0
Study: 12734907

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 76

Group type: COMPARATOR
Intervention: Stretching exercises
Number of subjects: 76
Study: 10943872

Group type: EXPERIMENTAL
Intervention: Leflunomide (20 mg/day after a 3-day 100 mg/day loading dose)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Methotrexate (increased stepwise to 15 mg/week)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Leflunomide and Methotrexate
Number of subjects: 39

Group type: COMPARATOR
Intervention: Leflunomide and Methotrexate (in subset fulfilling 20% response criteria)
Number of subjects: 39
Study: 9301427

Group type: EXPERIMENTAL
Intervention: Physical training (3 sessions a week, 60-80% of VO2max for 12 weeks followed by 14 weeks non-supervised)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (educational programme)
Number of subjects: 58
Study: 8330603

Group type: EXPERIMENTAL
Intervention: Propofol 2.79 +/- 0.4 mg kg‐1 h‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Midazolam 0.08 +/- 0.01 mg kg‐1 h‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Methohexitone 1.8 +/- 0.2 mg kg‐1 h‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no sedative agent)
Number of subjects: 30
Study: 3275752

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (CMF) with endocrine treatment (prednisone, oophorectomy)
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (CMF)
Number of subjects: 818
Study: 29401246

Group type: EXPERIMENTAL
Intervention: Lifastuzumab vedotin (LIFA) 2.4 mg/kg, intravenously, every 3 weeks (Q3W)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD) 40 mg/m2, intravenously, every 4 weeks (Q4W)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Lifastuzumab vedotin (LIFA)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD)
Number of subjects: 95
Study: 28453703

Group type: EXPERIMENTAL
Intervention: Definitive RT/CT (arm A)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Surgery (arm B)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: HeartV5 influence
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Causes of death
Number of subjects: 161
Study: 25306088

Group type: EXPERIMENTAL
Intervention: Oral olive oil
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral sunflower oil (control)
Number of subjects: 100
Study: 23547492

Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride (SnF2) dentifrice
Number of subjects: 120

Group type: COMPARATOR
Intervention: 0.3% triclosan dentifrice
Number of subjects: 120
Study: 21417739

Group type: EXPERIMENTAL
Intervention: Early palliative care consultation
Number of subjects: 67
Study: 18756586

Group type: EXPERIMENTAL
Intervention: Acarbose treatment
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 16492992

Group type: EXPERIMENTAL
Intervention: Succimer treatment
Number of subjects: 780

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Maternal IQ <70
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Maternal IQ >=70
Number of subjects: 780
Study: 12920628

Group type: EXPERIMENTAL
Intervention: Vitamin E treatment (400 IU/day for children <30 kg, 800 IU/day for children >30 kg)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Vitamin E treatment
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 9885327

Group type: EXPERIMENTAL
Intervention: Calcium carbasalate (equivalent to 900 mg aspirin) plus metoclopramide 10 mg (CM)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Ergotamine tartrate 1 mg plus caffeine 100 mg (EC)
Number of subjects: 296
Study: 8933892

Group type: EXPERIMENTAL
Intervention: Salbutamol (S)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (I)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Spontaneous resolution (R)
Number of subjects: 4
Study: 1991678

Group type: EXPERIMENTAL
Intervention: Adult Day Health Care (ADHC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Utilization and costs of health care
Number of subjects: 0
Study: 7102707

Group type: EXPERIMENTAL
Intervention: 3 percent acyclovir ointment
Number of subjects: 73

Group type: COMPARATOR
Intervention: 3 percent vidarabine ointment
Number of subjects: 73
Study: 31211178

Group type: EXPERIMENTAL
Intervention: naproxen 220 mg b.i.d.
Number of subjects: 78

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 78
Study: 28118410

Group type: EXPERIMENTAL
Intervention: Personalised invitation letter
Number of subjects: 13886

Group type: EXPERIMENTAL
Intervention: Personalised invitation letter + informative leaflet
Number of subjects: 13886

Group type: EXPERIMENTAL
Intervention: Personalised invitation letter + informative leaflet + personalised phone call
Number of subjects: 13886

Group type: COMPARATOR
Intervention: Control (spontaneous demand of cervical cancer screening)
Number of subjects: 13886
Study: 26738271

Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 or 25 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24382277

Group type: EXPERIMENTAL
Intervention: Bromocriptine (5 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22103890

Group type: EXPERIMENTAL
Intervention: Sequential Brief Adlerian Psychodynamic Psychotherapy (SB-APP)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Supervised Team Management (STM)
Number of subjects: 35
Study: 19480226

Group type: EXPERIMENTAL
Intervention: Consistent bedtime routine
Number of subjects: 405

Group type: COMPARATOR
Intervention: Usual bedtime routine (Control)
Number of subjects: 405
Study: 17718375

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 28
Study: 15499953

Group type: EXPERIMENTAL
Intervention: 0.5 ml 30% glucose in spray form
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.5 ml 30% glucose by syringe
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.5 ml sterile water by syringe
Number of subjects: 60
Study: 11483910

Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 44

Group type: COMPARATOR
Intervention: Men
Number of subjects: 44

Group type: COMPARATOR
Intervention: Follicular phase women
Number of subjects: 44

Group type: COMPARATOR
Intervention: Luteal phase women
Number of subjects: 44
Study: 9560127

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 169
Study: 7890017

Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hypocaloric Diet (HD)
Number of subjects: 0
Study: 2905154

Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg twice daily
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg twice daily
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 31156062

Group type: EXPERIMENTAL
Intervention: PCV9 vaccination
Number of subjects: 395
Study: 30489323

Group type: EXPERIMENTAL
Intervention: Abdominal Surgery Impact Scale scores in patients without postoperative complications
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Abdominal Surgery Impact Scale scores in patients with higher preoperative physical status
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Abdominal Surgery Impact Scale scores in men
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Abdominal Surgery Impact Scale scores in patients without postoperative stoma
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Abdominal Surgery Impact Scale scores in patients with shorter time to readiness for discharge (≤4 days)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Abdominal Surgery Impact Scale scores in patients with shorter length of stay (≤4 days)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Abdominal Surgery Impact Scale scores preoperatively
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Abdominal Surgery Impact Scale scores at 2 weeks postoperatively
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Abdominal Surgery Impact Scale scores at 4 weeks postoperatively
Number of subjects: 100
Study: 28768141

Group type: EXPERIMENTAL
Intervention: Fluoroquinolone-treated (enrofloxacin; Baytril® 100)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Nontreated control
Number of subjects: 288
Study: 26471159

Group type: EXPERIMENTAL
Intervention: Multi-component brief intervention including clinician advice, video message, health education booklet, and follow-up coaching sessions.
Number of subjects: 334

Group type: COMPARATOR
Intervention: Usual care and cancer screening information.
Number of subjects: 334
Study: 24649762

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) as monotherapy, performed 1 time per week for 4 weeks.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Drug treatment (control group).
Number of subjects: 30
Study: 21679343

Group type: EXPERIMENTAL
Intervention: Capsaicin 0.5mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Nocebo
Number of subjects: 42
Study: 18758349

Group type: EXPERIMENTAL
Intervention: Bone morphogenetic proteins (BMPs)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: recombinant BMP-2 (rBMP-2)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: recombinant BMP-7 (rhBMP-7)
Number of subjects: 383

Group type: COMPARATOR
Intervention: iliac crest bone graft (ICBG)
Number of subjects: 383
Study: 17119724

Group type: EXPERIMENTAL
Intervention: Excision of pterygia and sampling of normal conjunctiva
Number of subjects: 36
Study: 12787177

Group type: EXPERIMENTAL
Intervention: Screening for lung cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 11052952

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) with endurance training
Number of subjects: 16

Group type: COMPARATOR
Intervention: endurance training alone (placebo group)
Number of subjects: 16
Study: 8989735

Group type: EXPERIMENTAL
Intervention: Normal NaCl diet (120 mmol/day)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: High NaCl intake (240 mmol/day)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Low NaCl intake (20 mmol/day)
Number of subjects: 43
Study: 1299259

Group type: EXPERIMENTAL
Intervention: Dentin treated with GC Conditioner for 10 seconds, rinsed with distilled water, dried with oil‐free compressed air, placement of GIC, sheared 7 days post‐curing
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dentin rinsed with distilled water, dried with oil‐free compressed air, placement of GIC, sheared 7 days post‐curing
Number of subjects: 40
Study: 6329863

Group type: EXPERIMENTAL
Intervention: Cereal-fibre-rich diet (42.4 g dietary fibre/6.7 MJ)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Diabetic diet (18.9 g dietary fibre/6.7 MJ)
Number of subjects: 14
Study: 31146540

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (20 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 30577871

Group type: EXPERIMENTAL
Intervention: Operational program
Number of subjects: 5285

Group type: COMPARATOR
Intervention: Usual routine
Number of subjects: 5285
Study: 27327855

Group type: EXPERIMENTAL
Intervention: Minimal-dose S-ketamine (0.015 mg/kg/h infusion following a saline bolus)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose S-ketamine (0.25 mg/kg bolus and 0.125 mg/kg/h infusion for 48 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline bolus and infusion)
Number of subjects: 0
Study: 25003802

Group type: EXPERIMENTAL
Intervention: Treatment 3 (transportation plus prenatal/postpartum home visiting)
Number of subjects: 1138

Group type: EXPERIMENTAL
Intervention: Treatment 4 (transportation, screening, and prenatal, postpartum, and infant/toddler home visiting)
Number of subjects: 1138

Group type: COMPARATOR
Intervention: Combined control group (treatments 1 and 2)
Number of subjects: 1138

Group type: EXPERIMENTAL
Intervention: Treatment 2 (transportation plus developmental screening for infants and toddlers)
Number of subjects: 1138
Study: 22775763

Group type: EXPERIMENTAL
Intervention: CVD risk factors management
Number of subjects: 4107

Group type: EXPERIMENTAL
Intervention: Blood pressure management
Number of subjects: 4107

Group type: COMPARATOR
Intervention: Antihypertensive medication
Number of subjects: 4107

Group type: COMPARATOR
Intervention: Lipid management
Number of subjects: 4107

Group type: COMPARATOR
Intervention: Antiplatelet agent use
Number of subjects: 4107
Study: 19574331

Group type: EXPERIMENTAL
Intervention: INTERCOM programme (exercise training, education, nutritional therapy, smoking cessation counselling)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: INTERCOM programme
Number of subjects: 199

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 199
Study: 18797255

Group type: COMPARATOR
Intervention: Bottom-up attention condition with lateral blinking lights present
Number of subjects: 0

Group type: COMPARATOR
Intervention: Top-down attention condition with imperative stimuli on the right side
Number of subjects: 0
Study: 15615808

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg/day)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Furosemide (60 mg/day)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Combination of furosemide and hydrochlorothiazide
Number of subjects: 7

Group type: COMPARATOR
Intervention: Furosemide, hydrochlorothiazide, and their combination
Number of subjects: 7
Study: 12878504

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Azithromycin 500 mg
Number of subjects: 36
Study: 9500717

Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2a, 3 MU three times a week for 6 months (n = 16)
Number of subjects: 31

Group type: COMPARATOR
Intervention: No treatment (n = 15)
Number of subjects: 31
Study: 8562105

Group type: EXPERIMENTAL
Intervention: Amiodarone (46 patients: 5 mg/kg over 15 min and then 15 mg/kg over the subsequent 24 h for non-converting)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Propafenone (38 patients: 2 mg/kg over 15 min and then 10 mg/kg over the subsequent 24 h for non-converting)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 84

Group type: COMPARATOR
Intervention: Propafenone
Number of subjects: 84
Study: 2237825

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 602958

Group type: EXPERIMENTAL
Intervention: Continuous infusion of sisomicin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intermittent infusion of sisomicin
Number of subjects: 120
Study: 31842086

Group type: EXPERIMENTAL
Intervention: Detection-based pay-for-performance (P4P) intervention
Number of subjects: 8423

Group type: COMPARATOR
Intervention: Preintervention phase
Number of subjects: 8423
Study: 28865339

Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole and early enteral nutrition
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo and early enteral nutrition
Number of subjects: 102